Skip to content

effect of metoclopramide, pethidine and ketamine on the postoperative pain

The effect of subcutaneous injection of metoclopramide, pethidine and ketamine on the postoperative pain after inguinal hernia repair under general anesthesia

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20150106020588N7
Enrollment
104
Registered
2020-05-26
Start date
2018-04-04
Completion date
Unknown
Last updated
2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Inguinal Hernia. Condition 2: Surgical Incision Pain. Inguinal hernia Other acute postprocedural pain

Interventions

Intervention 1: First intervention group: in this group, 0.5 mg/kg of ketamine produced by Abidi company, which will be added to normal saline up to volume of 10 ml, will be injected subcutaneousely a

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: The patients with ASA(American Society of Anesthesiologists) class I-II who are undergoing elective inguinal hernia repair under general anesthesia

Exclusion criteria

Exclusion criteria: Uncontrolled systemic diseases Drug sensitivity to pethidine, metoclopramide and ketamine History of opium or alcohol addiction History of chronic pains in previous 6 months Any analgesic consumption in previous 24 hours History of Hypertension, Hyperthyroidism and psycologic disorders

Design outcomes

Primary

MeasureTime frame
Local pain in the incision site of the surgery. Timepoint: Within the initial 24 hours after the surgical repairing of inguinal hernia. Method of measurement: Visual Analog Scale (VAS).

Secondary

MeasureTime frame
Overall satisfaction of patients. Timepoint: 24 hours after the surgery. Method of measurement: Lickert scale from 1 to 5.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Azamian

Esfahan University of Medical Sciences

azamianza@yahoo.com+98 913 405 0702

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026